research Dupilumab in Inflammatory Skin Diseases: A Systematic Review
Dupilumab effectively treats various inflammatory skin diseases beyond its initial use for atopic dermatitis.
Search
for
Sort by
Research
120-150 / 1000+ results
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
research Efficacy and safety of ritlecitinib, an oral JAK3 /TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
research Baricitinib for the Treatment of Alopecia Areata
Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
research Efficacy and safety of baricitinib in patients with refractory alopecia areata
Baricitinib helped some patients with tough-to-treat hair loss regrow hair, but more research is needed on its safety.
research From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
JAK inhibitors are effective for treating moderate-to-severe alopecia areata.
research Efficacy of Local and Whole‐Body Phototherapy for the Treatment of Various Types of Alopecia Areata
Phototherapy effectively treats certain alopecia areata types, especially if started early.
research Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.
research Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
New medications could improve treatment for severe alopecia areata in Australia.
research Comparison of Current International Guidelines for the Management of Alopecia Areata—Comprehensive Review
International guidelines for treating alopecia areata vary, focusing on different treatment options and related health issues.
research Overlapping features of atopic dermatitis and alopecia areata: from pathogenesis to treatment
Atopic dermatitis and alopecia areata share immune and genetic factors, and targeted therapies may help both.
research Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
JAK inhibitors show promise for treating alopecia areata but have serious side effects.
research Revolutionary Approaches to Hair Regrowth: Follicle Neogenesis, Wnt/ß-Catenin Signaling, and Emerging Therapies
New hair regrowth therapies show promise but need more research.
research Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
research Effectiveness and safety of baricitinib in patients with moderate‐to‐severe refractory alopecia areata in real world: An open‐label, single‐center study
Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
research An Updated in the Management of Alopecia Areata
New treatments for alopecia areata show promise, but more research is needed to confirm their effectiveness.
research Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Diseases
New understanding and treatments for hair loss are improving, but more research is needed.
research Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
research 63253 A pilot study of efficacy and safety comparing 5% minoxidil emulsion and standard topical 5% minoxidil solution in the treatment of male androgenetic alopecia
research 10.1063/5.0132123.1
research AB032. Development of new treatment modality for male infertility by using phytopharmaceuticals
MOTILIPERM may help treat male infertility by reducing stress in cells.
research 45th Annual Scientific Meeting
research BC05 Technological and clinical demonstration of a skin ageing analysis prototype
The prototype for analyzing skin aging works technically and clinically.
research Contents Vol. 201, 2000
research Quality of life in children and adolescents with alopecia areata—A systematic review
Alopecia areata significantly worsens quality of life in children, causing embarrassment and social issues.
research Immunopathology and Immunotherapy of Inflammatory Skin Diseases
New targeted immunotherapies are improving treatment for inflammatory skin diseases.
research Serum Level of Macrophage Migration Inhibitory Factor (MIF) in Egyptians With Alopecia Areata and Its Relation to the Clinical Severity of the Disease
Higher MIF levels in alopecia areata patients suggest it could be a treatment target and disease predictor.
research Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
research Cosmeceutical and Dermatological Potential of Olive Mill Wastewater: A Sustainable and Eco-Friendly Source of Natural Ingredients
Olive mill wastewater can be used as a sustainable source of skin-benefiting ingredients.